

CSD/BSE&NSE/UFR/2025-26

13th August, 2025

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Meeting of Board of Directors of Suven Life Sciences Limited held on August 13, 2025

.....

With reference to the above subject and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company at its meeting held today i.e. 13th August, 2025, has taken on record and approved Unaudited Standalone and Consolidated Financial Results of the Company along with review reports of the Statutory Auditors for the quarter ended 30th June, 2025.

We are enclosing herewith the following documents:

- a) Un-audited Standalone and Consolidated Financial Results under Ind AS for quarter ended 30th June, 2025 and
- b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above

Update on patents during this period are accessible to everyone at below mentioned web link: www.suven.com/Patentupdates.aspx

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M.

For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary
M. No.: F12400

Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500034

STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

Rs. In Lakhs					
STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		Un-Audited	Refer note.7	Un-Audited	Audited
1	Income	(1)	(2)	(3)	(4)
	Revenue from operations	186.67	146.70	100.60	665.58
	Other Income	58.90	119.08	393.10	1,072.59
	Total income	245.57	265.78	493.70	1,738.17
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	597.56	606.61	468.96	2,082.49
	d) Finance costs	-	-	2.31	4.66
	e) Depreciation and amortisation expense	136.84	134.67	148.64	582.17
	f) R & D Expenses	518.77	848.73	458.98	3,043.16
	g) Other Expenses	470.27	182.78	181.40	733.67
	Total expenses	1,723.44	1,772.79	1,260.29	6,446.15
3	Profit before exceptional items & Tax (1-2)	(1,477.87)	(1,507.01)	(766.59)	(4,707.98)
4	Exceptional Items- (Ref Note:6)	-	-	-	-
5	Profit/(Loss) before Tax (3-4)	(1,477.87)	(1,507.01)	(766.59)	(4,707.98)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	-	-	-
	c) Tax of earlier years	-	-	-	-
7	Net Profit/ (Loss) for the period/year(5-6)	(1,477.87)	(1,507.01)	(766.59)	(4,707.98)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(1.50)	(4.64)	(0.45)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(1.50)	(4.64)	(0.45)	(5.99)
9	Total Comprehensive Income for the period (7+8)	(1,479.37)	(1,511.65)	(767.04)	(4,713.97)
10	Paid-up equity share capital	2,180.74	2,180.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	77,770.36
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(0.68)	(0.69)	(0.35)	(2.16)
	b) Diluted	(0.68)	(0.69)	(0.35)	(2.16)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



		Rs. In Lakhs			
		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		Un-Audited	Refer note.7	Un-Audited	Audited
1	Income	(1)	(2)	(3)	(4)
	Revenue from operations	186.67	146.70	100.60	665.58
	Other Income	59.98	122.25	400.83	1,089.69
	Total income	246.65	268.95	501.43	1,755.27
2	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	c) Employee benefits expense	597.56	606.61	468.96	2,082.49
	d) Finance costs	-	-	2.31	4.66
	e) Depreciation and amortisation expense	136.84	134.67	148.64	582.17
	f) R & D Expenses	4,148.84	3,732.50	2,491.87	14,396.18
	g) Other Expenses	515.10	189.66	193.62	764.27
	Total expenses	5,398.34	4,663.44	3,305.40	17,829.77
3	Profit before exceptional items , Tax (1-2)	(5,151.69)	(4,394.49)	(2,803.97)	(16,074.50)
4	Exceptional Items- (Ref Note:6)	-	-	-	-
5	Profit/(Loss) before Tax (3-4)	(5,151.69)	(4,394.49)	(2,803.97)	(16,074.50)
6	Tax Expenses				
	a) Current tax	-	-	-	-
	b) Deferred tax	-	-	-	-
	c) Tax of earlier years	-	-	-	-
7	Net Profit/ (Loss) for the period/year(5-6)	(5,151.69)	(4,394.49)	(2,803.97)	(16,074.50)
8	Other Comprehensive Income				
8.a	(i) Items that will not be reclassified to profit or loss	(1.50)	(4.64)	(0.45)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	(3.62)	(52.34)	-	(52.34)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(5.12)	(56.98)	(0.45)	(58.33)
9	Total Comprehensive Income for the period (7+ 8)	(5,156.81)	(4,451.47)	(2,804.42)	(16,132.83)
10	Paid-up equity share capital Face Value of the Share	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00
11	Other Equity	-	-	-	8,817.94
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	(2.36)	(2.02)	(1.29)	(7.37)
	b) Diluted	(2.36)	(2.02)	(1.29)	(7.37)
		(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13, 2025. The results for the quarter ended June 30, 2025 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) ESOP: For the quarter ended June 2025, the Company recognized an employee benefit expense (EBP) of Rs. 27.38 lakhs in accordance with Ind AS 102 - Share-based Payment. The cumulative EBP recognized as of June 2025 amounts to Rs.154.83 lakhs. During the quarter, out of 2,21,800 options under the 1st tranche, 1,93,500 options were exercised and the Company received ₹106.43 lakhs pursuant to the exercise of employee stock options under its SLSL ESOP 2020 scheme. As of the reporting date, the equity shares corresponding to these exercised options had not yet been allotted. The remaining unexercised options under the 1st tranche continue to be available for exercise by eligible employees until 06-May-2027.

6) Preferential Issue : The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025.

Each warrant is convertible into one equity share of face value ₹1 at an exercise price of ₹134 per share, within a period of 18 months from the date of allotment.

As per the terms of issue:

1. 25% of the warrant price is payable at the time of allotment.
2. The balance 75% is payable upon exercise of the warrant, prior to allotment of equity shares.

Break-up of the amounts received is as follows:

Particulars	Amount in Lakhs
25% upfront received from 23 allottees	21,441.00
Balance 75% received from 2 allottees	7,724.93
Total money received as on 30th June 2025	29,165.93

7) The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year.

Place : Hyderabad
Date: August 13, 2025



For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & MD
DIN: 00278028

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter ended June 30th, 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended.

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KARVY & CO

Chartered Accountants

(Firm Registration No .001757S)



AJAYKUMAR KOSARAJU

Partner

M.No. 021989

UDIN: 25021989BMLATS 4030



Place: Hyderabad

Date : 13/08/2025

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
CONSOLIDATED FINANCIAL RESULTS**

To
The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30,2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation')
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary




13/08/2025

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs.1.08 Lakhs, and total net loss after tax of Rs. (3,673.81) lakhs for the quarter ended June 30, 2025, and total comprehensive income of Rs. (3,677.44) Lakhs for the quarter ended June 30, 2025 as considered in the Statement. This interim financial information has been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)


AJAYKUMAR KOSARAJU
Partner
M.No. 021989
UDIN:25021989BMIAT T3253



Place: Hyderabad
Date : 13/08/2025

13/08/2025